VistaGen Therapeutics, Inc. Operating Cash Flow

Operating Cash Flow of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending December 30, 2020 was $-4.91 Million (a -553.9% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow increased by 95.64%
  • Annual Operating Cash Flow for 2020 was $-15.5 Million (a 6.63% increase from previous year)
  • Annual Operating Cash Flow for 2019 was $-14.5 Million (a 60.38% increase from previous year)
  • Annual Operating Cash Flow for 2018 was $-9.06 Million (a 24.73% increase from previous year)
  • Twelve month Operating Cash Flow ending December 30, 2020 was $-9.07 Million (a 10.0% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow decreased by -41.45% year-over-year
Trailing Operating Cash Flow for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
$-9.07 Million $-8.25 Million $-13.5 Million $-15.5 Million
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of VistaGen Therapeutics, Inc.

Most recent Operating Cash Flowof VTGN including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-4.91 $1.08 $-2.73 $-2.51 $-15.49
2019 $-4.08 $-4.14 $-4.76 $-3.56 $-14.53
2018 $-3.91 $-3.93 $-3.14 $-2.6 $-9.06
2017 $-2.44 $-1.88 $-2.13 $-1.29 $-7.26
2016 $-2.1 $-2.2 $-1.67 $-1.31 $-4.81
2015 $-1.17 $-1.51 $-0.82 $-0.89 $-2.77
2014 $-0.34 $-0.52 $-1.01 $-0.47 $-2.13
2013 $-0.34 $-0.58 $-0.73 $-0.97 $-3.46
2012 $-0.96 $-1.23 $-0.3 $-0.72 $-3.57
2011 $-1.06 $-0.7 $-1.09 $-0.0 $-0.83
2010 $-0.44 $-0.33 $-0.01

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.